Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Wasim A. Prates-Syed, Lorena C. S. Chaves, Karin P. Crema, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1409-1409
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Platforms, advances, and technical challenges in virus-like particles-based vaccines
Reeshu Gupta, Kajal Arora, Sourav Singha Roy, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Fábio Mambelli, Ana Carolina V. S. C. de Araujo, Jéssica Pires Farias, et al.
Pathogens (2025) Vol. 14, Iss. 1, pp. 23-23
Open Access | Times Cited: 1
COVID-19 Vaccines: Current and Future Perspectives
Luca Soraci, Fabrizia Lattanzio, Giulia Soraci, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 608-608
Open Access | Times Cited: 37
Electrostatic Features for the Receptor Binding Domain of SARS-COV-2 Wildtype and Its Variants. Compass to the Severity of the Future Variants with the Charge-Rule
Fernando Luís Barroso da Silva, Carolina Corrêa Giron, Aatto Laaksonen
The Journal of Physical Chemistry B (2022) Vol. 126, Iss. 36, pp. 6835-6852
Open Access | Times Cited: 30
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Armina Alagheband Bahrami, Ali Azargoonjahromi, Samin Sadraei, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 27
Nanocarrier vaccine therapeutics for global infectious and chronic diseases
Faizan Zarreen Simnani, Dibyangshee Singh, Paritosh Patel, et al.
Materials Today (2023) Vol. 66, pp. 371-408
Open Access | Times Cited: 18
COVID-19: The vaccine development strategies
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 645-667
Closed Access
The Second Life for Unused COVID-19 Vaccines: Towards Biosensing Application
Vincentas Mačiulis, Asta Lučiūnaitė, Mantvydas Usvaltas, et al.
Talanta (2025), pp. 127647-127647
Closed Access
Biophysics of SARS-CoV-2 spike protein’s receptor-binding domain interaction with ACE2 and neutralizing antibodies: from computation to functional insights
Fernando Luís Barroso da Silva, Karen Paco, Aatto Laaksonen, et al.
Biophysical Reviews (2025)
Closed Access
Microbial Nanoparticles in Biological Plant Protection
Tomasz Maciąg, Edmund Kozieł, Małgorzata Dudkiewicz, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2492-2492
Open Access
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
Anirudha Chattopadhyay, A. Abdul Kader Jailani, Bikash Mandal
Vaccines (2023) Vol. 11, Iss. 8, pp. 1347-1347
Open Access | Times Cited: 12
Photodynamic viral inactivation assisted by photosensitizers
Mohammad Sadraeian, Le Zhang, Farzaneh Aavani, et al.
Materials Today Physics (2022) Vol. 28, pp. 100882-100882
Closed Access | Times Cited: 21
Harnessing Nanovaccines for Effective Immunization─A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective
Amol D. Gholap, Juhi Gupta, Pallavi Kamandar, et al.
ACS Biomaterials Science & Engineering (2023) Vol. 10, Iss. 1, pp. 271-297
Closed Access | Times Cited: 10
Cell‐engineered virus‐mimetic nanovesicles for vaccination against enveloped viruses
Chungmin Han, Suyeon Kim, Youngjoo Seo, et al.
Journal of Extracellular Vesicles (2024) Vol. 13, Iss. 4
Open Access | Times Cited: 3
Harnessing Nasal Immunity with IgA to Prevent Respiratory Infections
John Joseph
Immuno (2022) Vol. 2, Iss. 4, pp. 571-583
Open Access | Times Cited: 17
Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases
Ejuan Zhang, Zhiyong Ma, Mengji Lu
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 11
Open Access | Times Cited: 14
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
Ramireddy Bommireddy, Shannon Stone, Noopur Bhatnagar, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 944-944
Open Access | Times Cited: 13
Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants
Andrei Neamțu, Francesca Mocci, Aatto Laaksonen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
Characterization of extracellular vesicle and virus-like particles by single vesicle tetraspanin analysis
Chungmin Han, Minsu Kang, Hyejin Kang, et al.
Sensors and Actuators B Chemical (2023) Vol. 382, pp. 133547-133547
Closed Access | Times Cited: 6
Viral protein-based nanoparticles (part 2): Pharmaceutical applications
Rocio Mellid-Carballal, Sara Gutierrez-Gutierrez, Carmen Rivas, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 189, pp. 106558-106558
Open Access | Times Cited: 6
Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?
Manish Dhawan, AbdulRahman A. Saied, Manish Sharma
Health Sciences Review (2023) Vol. 9, pp. 100127-100127
Open Access | Times Cited: 6
Downstream processing of virus‐like particles with aqueous two‐phase systems: Applications and challenges
Hui Yi Leong, Xiaoqian Fu, Pau Loke Show, et al.
Journal of Separation Science (2022) Vol. 45, Iss. 12, pp. 2064-2076
Closed Access | Times Cited: 10
Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants
Andrei Neamţu, Francesca Mocci, Aatto Laaksonen, et al.
Colloids and Surfaces B Biointerfaces (2022) Vol. 221, pp. 112986-112986
Open Access | Times Cited: 10
Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins
Jing Chen, Xu Wang, Letian Li, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 9
COVID-19 Vaccines for Adults and Children with Autoimmune Gut or Liver Disease
Monika Peshevska-Sekulovska, Plamena Bakalova, Violeta Snegarova, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2075-2075
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top